annual cash & cash equivalents:
$340.24M+$106.03M(+45.27%)Summary
- As of today (September 12, 2025), AKRO annual cash & cash equivalents is $340.24 million, with the most recent change of +$106.03 million (+45.27%) on December 31, 2024.
- During the last 3 years, AKRO annual cash & cash equivalents has risen by +$189.75 million (+126.10%).
- AKRO annual cash & cash equivalents is now at all-time high.
Performance
AKRO Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$742.32M+$56.02M(+8.16%)Summary
- As of today (September 12, 2025), AKRO quarterly cash & cash equivalents is $742.32 million, with the most recent change of +$56.02 million (+8.16%) on June 30, 2025.
- Over the past year, AKRO quarterly cash & cash equivalents has dropped by -$17.88 million (-2.35%).
- AKRO quarterly cash & cash equivalents is now -17.86% below its all-time high of $903.66 million, reached on March 31, 2024.
Performance
AKRO quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
AKRO Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +45.3% | -2.4% |
| 3 y3 years | +126.1% | +310.7% |
| 5 y5 years | +425.2% | +621.9% |
AKRO Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +126.1% | -17.9% | +310.7% |
| 5 y | 5-year | at high | +425.2% | -17.9% | +621.9% |
| alltime | all time | at high | >+9999.0% | -17.9% | >+9999.0% |
AKRO Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $742.32M(+8.2%) |
| Mar 2025 | - | $686.29M(-7.6%) |
| Dec 2024 | $340.24M(+45.3%) | $743.08M(+3.6%) |
| Sep 2024 | - | $717.25M(-5.6%) |
| Jun 2024 | - | $760.19M(-15.9%) |
| Mar 2024 | - | $903.66M(+64.3%) |
| Dec 2023 | $234.21M(-6.2%) | $550.01M(-0.9%) |
| Sep 2023 | - | $554.73M(-13.2%) |
| Jun 2023 | - | $639.44M(+86.3%) |
| Mar 2023 | - | $343.22M(-2.3%) |
| Dec 2022 | $249.77M(+66.0%) | $351.45M(-6.0%) |
| Sep 2022 | - | $374.00M(+106.9%) |
| Jun 2022 | - | $180.72M(+9.3%) |
| Mar 2022 | - | $165.38M(-12.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2021 | $150.48M(-19.6%) | $188.26M(-12.5%) |
| Sep 2021 | - | $215.08M(-6.5%) |
| Jun 2021 | - | $230.03M(-8.0%) |
| Mar 2021 | - | $249.98M(-6.9%) |
| Dec 2020 | $187.24M(+189.0%) | $268.39M(-8.0%) |
| Sep 2020 | - | $291.87M(+183.8%) |
| Jun 2020 | - | $102.83M(-17.9%) |
| Mar 2020 | - | $125.28M(-8.1%) |
| Dec 2019 | $64.79M(-14.7%) | $136.40M(-7.7%) |
| Sep 2019 | - | $147.84M(-9.1%) |
| Jun 2019 | - | $162.65M(+133.0%) |
| Mar 2019 | - | $69.80M(-8.1%) |
| Dec 2018 | $75.97M(>+9900.0%) | $75.97M(>+9900.0%) |
| Dec 2017 | $598.00K | - |
| Dec 2017 | - | $598.00K |
FAQ
- What is Akero Therapeutics, Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Akero Therapeutics, Inc.?
- What is Akero Therapeutics, Inc. annual cash & cash equivalents year-on-year change?
- What is Akero Therapeutics, Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Akero Therapeutics, Inc.?
- What is Akero Therapeutics, Inc. quarterly cash & cash equivalents year-on-year change?
What is Akero Therapeutics, Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of AKRO is $340.24M
What is the all time high annual cash & cash equivalents for Akero Therapeutics, Inc.?
Akero Therapeutics, Inc. all-time high annual cash & cash equivalents is $340.24M
What is Akero Therapeutics, Inc. annual cash & cash equivalents year-on-year change?
Over the past year, AKRO annual cash & cash equivalents has changed by +$106.03M (+45.27%)
What is Akero Therapeutics, Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of AKRO is $742.32M
What is the all time high quarterly cash & cash equivalents for Akero Therapeutics, Inc.?
Akero Therapeutics, Inc. all-time high quarterly cash & cash equivalents is $903.66M
What is Akero Therapeutics, Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, AKRO quarterly cash & cash equivalents has changed by -$17.88M (-2.35%)